10,480 Shares in West Pharmaceutical Services, Inc. (WST) Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. purchased a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 10,480 shares of the medical instruments supplier’s stock, valued at approximately $1,009,000.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of West Pharmaceutical Services by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 6,555,351 shares of the medical instruments supplier’s stock valued at $619,612,000 after purchasing an additional 114,507 shares during the period. BlackRock Inc. boosted its position in shares of West Pharmaceutical Services by 7.1% in the 2nd quarter. BlackRock Inc. now owns 6,217,894 shares of the medical instruments supplier’s stock valued at $587,715,000 after purchasing an additional 412,858 shares during the period. State Street Corp boosted its position in shares of West Pharmaceutical Services by 2.8% in the 2nd quarter. State Street Corp now owns 2,511,108 shares of the medical instruments supplier’s stock valued at $237,351,000 after purchasing an additional 67,937 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of West Pharmaceutical Services by 10.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 935,685 shares of the medical instruments supplier’s stock valued at $88,441,000 after purchasing an additional 86,022 shares during the period. Finally, Hermes Investment Management Ltd. boosted its position in shares of West Pharmaceutical Services by 3.3% in the 3rd quarter. Hermes Investment Management Ltd. now owns 908,655 shares of the medical instruments supplier’s stock valued at $87,467,000 after purchasing an additional 28,955 shares during the period. Institutional investors and hedge funds own 90.10% of the company’s stock.

Several equities research analysts recently issued reports on the company. Stephens assumed coverage on West Pharmaceutical Services in a research note on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price objective for the company. Wells Fargo & Company increased their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. Jefferies Group LLC raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their price objective for the stock from $96.00 to $115.00 in a research note on Friday, September 15th. BidaskClub downgraded West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. West Pharmaceutical Services presently has an average rating of “Hold” and an average target price of $106.00.

Shares of West Pharmaceutical Services, Inc. (WST) opened at $101.65 on Friday. The stock has a market capitalization of $7,547.82, a PE ratio of 43.81, a P/E/G ratio of 2.17 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87. West Pharmaceutical Services, Inc. has a one year low of $76.87 and a one year high of $103.36.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.14. The firm had revenue of $398.20 million during the quarter, compared to the consensus estimate of $386.02 million. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.53 EPS. analysts predict that West Pharmaceutical Services, Inc. will post 2.76 earnings per share for the current year.

WARNING: “10,480 Shares in West Pharmaceutical Services, Inc. (WST) Purchased by Crossmark Global Holdings Inc.” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/12/10480-shares-in-west-pharmaceutical-services-inc-wst-purchased-by-crossmark-global-holdings-inc.html.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply